🇺🇸 FDA
Patent

US 7691878

Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

granted A61PA61P1/00

Quick answer

US patent 7691878 (Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists) held by Theravance, Inc. expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Apr 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P1/00